December 26, 2025 07:30 pm (IST)

Make this your homepage

Health

Christmas vandalism sparks mass arrests in Raipur; Assam acts too with crackdown on 'religious intolerance' | BJP's VV Rajesh becomes Thiruvananthapuram Mayor after party topples Left's 45-year-rule in city corporation | ‘I can’t bear the pain’: Indian-origin father of three dies after 8-hour hospital wait in Canada hospital | Janhvi Kapoor, Kajal Aggarwal, Jaya Prada slam brutal lynching in Bangladesh, call out ‘selective outrage’ | Tarique Rahman returns to Bangladesh after 17 years | Shocking killing inside AMU campus: teacher shot dead during evening walk | Horror on Karnataka highway: sleeper bus bursts into flames after truck crash, 9 killed | PM Modi attends Christmas service at Delhi church, sends message of love and compassion | Delhi erupts over lynching of Hindu man in Bangladesh; protest outside High Commission | Targeted killing sparks global outrage: American lawmakers condemn mob lynching of Hindu man in Bangladesh

COVID Naval Vaccine

Wikipedia Commons

Covaxin maker's nasal Covid vaccine cleared for emergency use, announces Mansukh Mandaviya

India Blooms News Service | @indiablooms | Sep 06, 2022, at 10:29 pm

#Covaxin #CovaxinNavalVaccine #COVID19

New Delhi: Bharat Biotech’s needle-free intranasal vaccine against Covid-19 has gained emergency use approval in India Union health minister Mansukh Mandaviya confirmed on Tuesday.

The Minister said the step will further strengthen India's collective fight against the pandemic.

The vaccine could be delivered through naval route.

This step will further strengthen our collective fight against the pandemic.

India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership.

With the science-driven approach & Sabka Prayas, we will defeat COVID-19.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022

"Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation," the Minister tweeted.

Big Boost to India's Fight Against COVID-19!

Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022

"This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership. With the science-driven approach & Sabka Prayas, we will defeat COVID-19," he said.

India reported 4,417 new Covid-19 cases while the toll went up by 23 in the last 24 hours, the Union Health Ministry said Tuesday.

In the same span of time, 6,032 Covid-19 patients have recovered from across the country.

The active cases, which now stand at 52,336, forms 0.12% of the total number of infections.

The recovery rate now stands at 98.69%.

Under the national vaccination drive, 213.72 crore anti-Covid vaccine doses have been administered in the country.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.